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Abstract
Background: The administration of hepatitis B immunoglobulin followed by hepatitis B vaccine can result in a 
protective efficacy of almost 90% in mother-to-child transmission of hepatitis B virus (HBV). However, little is known 
about immunity against HBV infection in children after immunoprophylactic treatment. We tried to assess the 
association between T-cell responses and viremia in children after successful prophylactic treatment.
Methods: Thirteen children and their 8 HBV carrier mothers (8 families), who were positive for human leukocyte 
antigen (HLA)-A24, were enrolled in this study. All of the 13 children received immunoprophylactic treatment and 
became negative for hepatitis B surface antigen (HBsAg) after birth. HBV-specific cytotoxic T lymphocyte (CTL) 
responses were evaluated using IFNγ - enzyme-linked immunosorbent spot (ELISPOT) and major histocompatibility 
complex class I peptide pentamer assays. Serum HBV DNA was measured by real-time PCR.
Results: Significant HBV-specific T-cell responses were detected in 2 (15%) of the 13 children by ELISPOT. However, the 
frequency of HLA-A24-HBV-specific CTLs was very low in both HBV carrier mothers and children using pentamers. Of 
the 13 children, 4 (31%) were positive for serum HBV DNA. However, the levels of serum HBV DNA were 100 copies/ml 
or less. One of the 2 children in whom significant HBV-specific CTL responses were detectable was positive for serum 
HBV DNA.
Conclusions: HBV core and polymerase-specific T-cell responses were detected and a low-dose viremia was observed 
in children after successful immunoprophylaxis treatment. Although the presence of viremia was not related to HBV-
specific T-cell responses, CTLs might play a role in the control of HBV infection in children born to HBsAg-positive 
mothers after immunoprophylactic treatment.
Background
Worldwide, hepatitis B virus (HBV) is a common cause of
liver disease. An estimated 350 million persons are
chronically infected with HBV, and these individuals have
a 15-25% risk of dying from HBV-related disease, includ-
ing liver cirrhosis, hepatic decompensation, and hepato-
cellular carcinoma [1,2]. HBV is 100 times more
infectious than human immunodeficiency virus and is
transmitted by percutaneous or mucosal exposure to
infected blood or other body fluids. Perinatal transmis-
sion, household contact, sexual contact, blood transfu-
sion, and unsterilized injection are known as common
routes of HBV transmission. The risk of mother-to-child
transmission is 5-20% if the mother is positive for hepati-
tis B surface antigen (HBsAg) alone, but 90% if the
mother is positive for hepatitis B e antigen (HBeAg) [3].
To prevent mother-to-child transmission at or around
birth, hepatitis B immunoglobulin (HBIG) is adminis-
trated for newborns born to HBsAg-positive mothers
within 12 hr after birth combined with a three-dose series
hepatitis B vaccine in many countries, including Japan
[4,5]. HBIG has high levels of antibodies to HBsAg (anti-
HBs), which are neutralizing antibodies against HBV.
HBIG is immediately effective and protective for a few
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months after birth. However, the levels of anti-HBs
decrease over time. Therefore, active vaccination is
required to sustain sufficient levels of anti-HBs to protect
young infants from HBV infection. This combination
strategy can show a protective efficacy of almost 90% and
results in fewer than 5% of infants becoming HBV carri-
ers [6-8].
Little is known about immunity from HBV infection in
children after successful immunoprophylactic treatment,
resulting in several questions about immunity post-vacci-
nation. For example, it remains controversial whether the
appearance of anti-HBs in children born to HBsAg-posi-
tive mothers implies complete protection from HBV
infection after birth. Previous studies showed that serum
HBV DNA was detected by polymerase chain reaction
(PCR) in children born to HBsAg-positive mothers even
after anti-HBs were induced by hepatitis B vaccine [9,10].
These findings suggested that children born to HBsAg-
positive mothers have a risk of becoming HBV carriers
even if immunoprophylactic treatment was successfully
administered. Although the levels of serum HBV DNA
are low in these anti-HBs-positive children after immu-
noprophylactic treatment, it is nevertheless a concern
that reactivation of HBV replication could occur if these
children receive immunosuppressive therapy.
In addition, the responses of HBV-specific cytotoxic T
lymphocytes (CTLs) have never been evaluated in chil-
dren after prophylactic treatment. HBV-specific CTLs
play a major role in the control of HBV infection [11].
Because hepatitis B vaccine is derived from surface pro-
tein, theoretically Th2 cytokines associated with helper T
lymphocytes are produced in response to vaccination
[12]. To stimulate major histocompatibility complex
(MHC) Class I restricted CD8+ CTLs, endogenous pep-
tides processing and presentation is required. Although
HBs peptide-specific CTLs can be induced by hepatitis B
vaccine, whether CTL responses to other peptides
derived from core and polymerase regions are primed
remains unclear. There is, therefore, a possibility that
HBV-core protein or -polymerase protein-specific CTLs
would be detectable in children born to HBsAg-positive
mothers if these children were exposed to HBV tran-
siently or persistently at or after birth.
The aim of this study was to clarify the association
between HBV-specific CTL responses and HBV viremia
in children born to HBsAg-positive mothers after suc-
cessful immunoprophylactic treatment. HBV-specific
CTL responses were evaluated using enzyme-linked
immunosorbent spot (ELISPOT) and MHC Class I pep-
tide pentamer assays. Because human leukocyte antigen
(HLA)-A24 is the most common HLA type in Japan,
HBV-specific HLA-A24-restricted CTL epitopes were
used for assays. Serum HBV DNA was measured by real-
time PCR, which is a powerful tool for the detection of
HBV DNA. Our data suggest that low-level viremia may
occur and that this may be associated with priming of
CTL responses even after apparently successful immuno-
prophylaxis.
Methods
Patients
This cross sectional study was approved by the Ethics
Committee. Informed consent for study participation was
obtained from the patients or their parents. Between
2002 and 2007, fifty-one women [HBeAg positive, n = 18;
antibodies to hepatitis B e antigen (anti-HBe) positive, n
= 33] [age range: 18-51 years; mean age ± SD: 34.4 ± 7.7
years] with chronic hepatitis B were followed in our
department (Figure 1). All of the women were positive for
HBsAg and negative for anti-HBs. None of them had
received any anti-viral treatment before, during, or after
delivery. Of the 51 women with chronic hepatitis B infec-
tion, 40 were mothers (HBeAg positive, n = 15; anti-HBe
positive, n = 25). HLA typing using flow cytometry was
performed in the 40 mothers, of whom 28 (HBeAg posi-
tive, n = 11; anti-HBe positive, n = 17) were positive for
HLA-A24. Of the 28 HLA-A24-positive mothers, 25
(HBeAg positive, n = 10; anti-HBe positive, n = 15) were
followed with their children in our department. The 25
mothers had 33 children (male/female = 16/17; age range:
0-22 years; mean age ± SD: 5.3 ± 4.4 years). Of the 33 chil-
dren, 7 children were positive for HBsAg and the remain-
ing 26 children were negative for HBsAg. Of the 33
children, 16 were positive for HLA-A24. Of the 16 chil-
dren, 3 were chronically infected with HBV. These 16
HLA-A24-positive children were born from 11 of the 25
HLA-A24-positive mothers. Therefore, both mothers
and children were positive for HLA-A24 in 11 families.
Of the 11 families, 8 had 13 children who were negative
for HBsAg. The 13 children (male/female = 6/7; age
range: 0-13 years; mean age ± SD: 5.4 ± 3.4 years) and
their 8 HBV carrier mothers (HBeAg positive, n = 2; anti-
HBe positive, n = 6, age range: 22-43 years; mean age ±
SD: 31.3 ± 7.6 years) were enrolled in this study (Figure
1). During the follow-up period, blood samples were col-
lected from all patients.
Monoclonal antibodies and synthetic peptides
Anti-HLA-A23, 24 monoclonal antibodies (mAbs) were
purchased from One Lambda (Canoga Park, CA, USA).
Goat anti-mouse immunoglobulin (IgG)-FITC Abs were
purchased from Immunotech (Marseille, France). The
HLA-A*2402 restricted HBV-specific CTL epitope core
117-125 (EYLVSFGVW) and HLA-A*2402-restricted
HBV-specific CTL epitope Pol 756-764 (KYTSFPWLL)
were previously identified [13]. These peptides were pur-
chased from Nippi Research Institute of BiomatrixKomatsu et al. BMC Infectious Diseases 2010, 10:103
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(Tokyo, Japan). Peptide purity was determined by mass
spectrometry and high-pressure liquid chromatography.
HLA typing
Detection of HLA-A24 was performed by flow cytometry
using the HLA-A23, 24 mAbs as we described previously
[14]. Because it is well established that HLA-A23 antigen
is very rarely detected in Japanese populations [15,16],
the HLA-A23, 24-positive subjects were considered to be
positive for HLA-A24. In brief, 200 μL of EDTA or hepa-
rinized whole blood was stained with HLA-A23, 24 mAb
for 20 minutes at 4°C. Whole blood stained with anti-
HLA-A23, 24 mAb was washed with PBS. After incuba-
tion for 20 minutes at 4°C with FITC-labeled mouse IgG,
the blood was washed again with PBS and lysed using
FACS lysis solution (Becton Dickinson Sciences, San Jose,
CA, USA). Samples were analyzed with a FACS Calibur
machine (BD Bioscience, Becton Dickinson) using Cell-
Quest software (BD Bioscience), after compensation was
checked using freshly stained peripheral blood mononu-
clear cells (PBMCs).
Pentamer assay
PBMCs were isolated from heparinized venous blood by
density gradient sedimentation using Ficoll-Hypaque
(Lymphoprep; Axis Shield, Oslo, Norway). PBMCs were
stained with R-phycoerythrin (PE)-labeled Pro5 MHC
Pentamer HLA-A*2402/EYLVSFGVW and HLA-
A*2402/KYTSFPWLL (Proimmune, Oxford, UK) accord-
ing to the manufacturer's instructions. In brief, 10 μL of
labeled Pentamer was added to a million PBMCs and
mixed by pipetting. Samples were incubated at room
temperature for 10 minutes, shielded from the light. Cells
were washed with 2 mL of PBS, and then 1 μL of anti-
CD8 FITC was added to the samples, which were then
mixed by pipetting. The samples were incubated at 4°C
for 20 minutes, shielded from the light, and then the cells
were washed twice with PBS. Cells were stored in Cell Fix
buffer (Becton Dickinson Immunocytometry Systems) at
4°C until analysis. Samples were analyzed with a FACS
Calibur using CellQuest software, after compensation
was checked using freshly stained PBMCs. On the basis
of a previous study, 0.04% of total CD8-positive cells were
Figure 1 Subject enrollment.
n = 51
Women who were mothers  
Mothers who were positive for 
HLA-A24  
Mothers whose children were 
positive for HLA-A24
Women who were positive for HBsAg
n = 40
n = 28
Both mothers and children were positive for HLA-A24,
but children were negative for HBsAg
8 families
(8 mothers, 13 children)
n = 11
Both mothers and children were positive 
for HBsAg and HLA-A24 
3 families
(3 mothers, 3 children)Komatsu et al. BMC Infectious Diseases 2010, 10:103
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considered to show non-specific binding in HBV infec-
tion [17].
ELISPOT assay
PBMCs were isolated from heparinized venous blood by
density gradient sedimentation using Ficoll-Hypaque
(Lymphoprep; Axis Shield, Oslo Norway). Fresh PBMCs
were plated in 96-well polyvinylidene plates (Milipore,
Bedford, MA, USA) that had been precoated with 0.5 μg/
ml anti-IFN-γ-mAb (Mabtech, Stockholm, Sweden). The
peptides were added in a volume of 10 ul, and then
PBMCs were added at 50,000-100,000 cells/well in a vol-
ume of 190 μl. The final concentration of core 117-125
(EYLVSFGVW) and pol 756-764 (KYTSFPWLL) was 5
μM. The plates were incubated overnight at 37°C in 5%
CO2 atmosphere and washed in PBS before the addition
of the second biotinylated anti-IFN-γ-mAb (Mabtech) at
0.5 μg/ml, followed by incubation at room temperature
for 100 min. After the plates were washed, streptavidin-
conjugated alkaline phosphatase (Mabtech) was added at
room temperature, and the samples sat for 40 minutes.
Individual cytokine-producing cells were detected as
dark spots after a 20-minute reaction with 5-bromo-4-
chloro-3-indolyl phosphate and nitro blue tetrazolium
using an alkaline phosphatase-conjugated substrate (Bio-
Rad Laboratories, Hercules, CA, USA). The number of
specific T cells was calculated by subtracting the negative
control values and expressed as the number of spot-form-
ing units per 106  P B M C s .  W e l l s  w e r e  c o n s i d e r e d  t o
exhibit a significant HBV-specific T-cell response if they
had values of least twice as great as the background value
and the number of spots was more than 50.
Real-time PCR assay
To evaluate the relation between HBV-specific T-cell
responses and viremia, we examined whether HBV vire-
mia was present in HBsAg-negative children. Real-time
PCR is a sensitive method for detecting HBV DNA. We
used the QIAamp UltraSens Virus DNA kit (QIAGEN,
Valencia, CA, USA) to extract virus DNA according to
the manufacturer's instructions. To enhance the detec-
tion, HBV DNA was extracted from 1 mL of serum and
extracted DNA was concentrated. The extracted DNA
was dissolved in 60 μL of elution buffer, and 10 μL of this
solution was used for real-time PCR. Quantification of
HBV DNA levels was performed using the genotype-
independent real-time PCR method described previously
[18]. In brief, PCR was performed on a 50-μL reaction
mixture containing 25 μL TaqMan Universal PCR master
mix (Applied Biosystems, Foster City, CA, USA) with 0.2
mM primers, 0.1 mM probes, and 10 μL extracted DNA.
The PCR program consisted of an initial pre-cycle incu-
bation at 50°C for 2 min and 95°C for 10 min, followed by
55 cycles of 95°C for 15 s and 60°C for 1 min. The PCR
assay was performed in a MX3000P machine (Strata-
gene), and the results were analyzed with MxPro software
(version 3.0). This assay has a quantitative detection limit
of 80 copies/mL. Therefore, this in-house PCR was as
sensitive as commercially available real-time PCR such as
the COBAS TaqMan HBV test (Roche).
Statistical analysis
The Chi-square test and Fisher's exact tests were used to
compare frequencies. Results are presented as the mean
± SD. Means were compared using Student's t-test or the
Mann Whitney test. A P-value of .05 or less was consid-
ered to indicate statistical significance.
Results
Characteristics of children and HBV carrier mothers
T o  e v a l u a t e  t h e  i m m u n i t y  i n  c h i l d r e n  w i t h  s u c c e s s f u l
immunoprophylactic treatment, we classified the chil-
dren into two groups according to their HBsAg status.
One group was the children who received immunopro-
phylactic treatment (HBIG combined with a 3-dose series
hepatitis B vaccine) after birth and remained negative for
HBsAg (13 children from 8 families) (Table 1). The other
group was the children who were positive for HBsAg (3
children from 3 families) (Table 2). Of the 3 HBsAg-posi-
tive children, one (C10) did not receive immunoprophy-
lactic treatment and became an HBV carrier. Despite
immunoprophylactic treatment, the remaining two chil-
dren in this group also became HBV carriers.
Characteristics of HBsAg-negative children and their
mothers are shown in Table 1. Among the parents of chil-
dren with successful immunoprophylactic treatment, 2
mothers were positive for HBeAg and the remaining 6
were negative for HBeAg. The levels of serum alanine
aminotransferase (ALT) (normal range: <35 IU/L) were
slightly elevated in one mother (M5). On the other hand,
the levels of serum ALT were normal in all children with
successful immunoprophylactic treatment. Although 10
mIU/mL or more was considered a protective level of
serum anti-HBs, the level of serum anti-HBs was less
than 10 mIU/mL in 4 children (C6a, C6b, C6c, and C7a).
Antibodies to hepatitis B core (anti-HBc) are considered
to be a marker of present or past infection. Two children
(C3b and C8) were positive for anti-HBc. Because one
child was a six-month-old baby, it was thought that his
maternal anti-HBc could cross the placenta at birth.
Table 2 shows the characteristics of HBsAg-positive
children and mothers. All of the children and mothers
were positive for HBeAg. The levels of serum ALT were
normal in all of these children and mothers.
ELISPOT assays
We evaluated the function of HBV-specific T-cells in
HBsAg-negative children (those who had received suc-K
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Table 1: Patient characteristics, IFN-γ enzyme-linked immunosorbent spot, and serum HBV DNA levels of children with successful prophylactic treatment and their 
mothers.
Patient ID* Age
(years)
Gender Levels of serum 
hepatitis B 
surface 
antibodies
(mIU/mL)
Hepatitis B e 
antigen status
Hepatitis B core 
antibody status
Levels of serum 
ALT (IU/L)
† core 117-125
(spots/106 
PBMCs)
† pol 756-764
(spots/106 
PBMCs)
Levels of serum 
hepatitis B virus 
DNA
(copies/mL)
M1 22 Pos Pos 18 14.1 17.6 > 108.8
C1 2 Female 84.7 Neg 16 0 5.0 100
M2 28 Neg Pos 13 0 0 104.0
C2 2 Male 40.6 Neg 17 0 8.9 80
M3 43 Neg Pos 10 4.5 0.9 103.2
C3a 11 Female 16.2 Neg 8 0 6.5 Neg
C3b 6 Male 172.1 Pos 17 0 0 Neg
M4 32 Neg Pos 11 30.8 47.3 103.1
C4 6 Male 28.2 Neg 15 13.9 94.4 Neg
M5 34 Neg Pos 37 0 0 103.0
C5a 8 Female 118.9 Neg 20 12.5 0 Neg
C5b 6 Female 63.4 Neg 13 68.0 114.3 80
M6 32 Neg Pos 17 48.2 8.2 103.7
C6a 6 Female 6.3 Neg 11 0 0 Neg
C6b 4 Female <5 Neg 12 40.0 0 Neg
C6c 2 Male <5 Neg 11 2.9 29.4 Neg
M7 40 Pos Pos 14 9.8 18.5 108.1
C7a 13 Male <5 Neg 18 0 0 Neg
C7b 4 Female 34.2 Neg 11 0 0 Neg
M8 22 Neg Pos 15 0 0 104.3
C8 0 Male 252.9 Pos 17 29.1 0 80
* M and C indicate mother and child, respectively. Number indicates family ID. † More than 50 spots/106 PBMCs were defined as a significant HBV-specific T-cell response. PBMCs, peripheral blood 
mononuclear cells. Pos, positive Neg, negativeKomatsu et al. BMC Infectious Diseases 2010, 10:103
http://www.biomedcentral.com/1471-2334/10/103
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cessful prophylactic treatment for mother-to-child trans-
mission), HBsAg-positive children, and HBsAg-positive
carrier mothers. IFNγ-ELISPOT assays were performed
in both children and mothers. The results of ELISPOT
assays in the group of HBsAg-negative children (n = 13)/
HBsAg-positive mothers (n = 8) and HBsAg-positive
children (n = 3)/HBsAg-positive mothers (n = 3) are
shown in Tables 1 and 2, respectively. Surprisingly, a sig-
nificant HBV-specific T-cell response (> 50 spots/106
PBMCs) was detectable in 2 of 13 HBsAg-negative chil-
dren (C4: pol 756-764; C5b: core 117-125, pol 756-764).
However, anti-HBc antibodies were not detectable in the
2 children who showed significant HBV-specific T-cell
responses.
No significant HBV-specific T-cell response was
detected in the mothers of HBsAg-negative children.
Likewise, none of the HBsAg-positive children had a sig-
nificant response (Table 2), but one HBV carrier mother
showed a significant response (M9; pol 756-764) (Table
2). Although there was no significant difference in the
frequency of HBV-specific T-cell response to the two
HBV-derived peptides between HBsAg-negative chil-
dren and HBsAg-positive children (Table 3), these find-
ings suggested that HBsAg-negative children who
received prophylactic treatment have a potential to pro-
duce HBV-specific T-cell responses.
HBV pentamer analysis
HBV-specific CTLs play a crucial role in both virus clear-
ance and the pathogenesis of hepatic cell injury. In partic-
ular, CTLs show a stronger response in cases of acute
infection than in patients with chronic infection. MHC
Class I peptide complexes (pentamers) can detect circu-
lating HBV -specific CD8+ T cells. W e performed pen-
tamer staining to detect HBV-specific CD8+ T cells in
HBsAg-negative children (n = 10) and their mothers (n =
5 )  ( T a b l e  4 ) .  N o n e  o f  t h e  H B s A g - n e g a t i v e  c h i l d r e n
showed a high frequency of pentamer-positive cells (Pen-
tamer/CD8, core 117-125: 0.003 ± 0.005%, pol 756-764:
0.002 ± 0.002%). Similarly, HBsAg carrier mothers did
not show a high frequency of HBV-specific CD8+ T cells
(Pentamer/CD8, core 117-125: 0.004 ± 0.005%, pol 756-
764: 0.001 ± 0.002%). Because there was no study partici-
pant who showed more than 0.04% in frequency of HBV-
specific CD8+ T cells in this study, neither the HBsAg-
negative children nor their mothers were classified as
showing a positive response in this study. However, we
did not have any positive controls. Therefore, further
studies are required to interpret these results appropri-
ately.
Serum HBV DNA, serum HBsAb, and HBeAg status of 
mothers
The levels of serum HBV DNA are shown in Table 1. Of
the 13 HBsAg-negative children, 4 (31%) were positive for
serum HBV DNA. However, the levels of serum HBV
DNA were between 100 and 80 copies/mL. All of the chil-
dren with HBV viremia were positive for anti-HBs.
Although all of the 13 HBsAg-negative children received
prophylactic treatment, anti-HBs were not detectable in 3
of these children (23%). One of the children with viremia
(C1) was born to an HBeAg-positive mother, and the
remaining 3 children with viremia (C2, C5b, and C8) were
born to HBeAg-negative mothers. Of 2 children who
showed a significant response to HBV peptides in
ELISPOT assay, one child (C5b) was positive for serum
HBV DNA. Therefore, there was no association between
Table 2: Patient characteristics, IFN-γe nzyme-linked immunosorbent spot, and serum HBV DNA levels of hepatitis B 
surface antigen-positive children and their mothers.
Patient ID* Age
(years)
Gender Levels of 
serum ALT
(IU/L)
Hepatitis B e 
antigen 
status
† core 117-125
(Spots/106 
PBMCs)
† pol 756-764
(Spots/106 
PBMCs)
Levels of 
serum 
hepatitis B 
virus DNA
(copies/mL)
M9 33 18 Pos 12.6 53.9 >108.8
C9 3 Male 33 Pos 12.8 5.7 108.2
M10 47 21 Pos 12.8 30.8 108.3
C10 22 Female 30 Pos 20.7 26.2 108.6
M11 32 17 Pos 22.5 48.4 108.6
C11 4 Female 16 Pos 7.0 5.3 108.7
* M and C indicate mother and child, respectively. Number indicates family ID. † More than 50 spots/106 PBMCs were defined as a significant 
HBV-specific T-cell response. PBMCs, peripheral blood mononuclear cells. Pos, positive Neg, negativeKomatsu et al. BMC Infectious Diseases 2010, 10:103
http://www.biomedcentral.com/1471-2334/10/103
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the detection of serum HBV DNA and HBV-specific T-
cell responses.
Discussion
Newborns born to HBsAg-positive mothers are usually
exposed to HBV around delivery, except those who con-
tract intra-uterine infection. The administration of HBIG
containing neutralizing antibodies can prevent newborns
from HBV infection for a few months after birth. Active
hepatitis B vaccine following HBIG administration
induces active immunity and stimulates the production of
sustained neutralizing antibodies against HBV in new-
borns. However, the overall immune response induced by
both HBIG and hepatitis B vaccine in the prevention of
mother-to-child transmission remains unclear. Although
a small proportion of newborns treated with HBIG com-
bined with hepatitis B vaccine become positive for HBV
DNA from cord blood or peripheral blood transiently at
or after birth, they eventually show no viremia [9,10,19].
In contrast, a proportion of newborns receiving HBIG
combined with hepatitis vaccine become positive for
anti-HBs, but HBV viremia persists after birth [10]. These
observations suggest that newborns can be suffering from
HBV viremia transiently or for several years after birth,
despite having received immunoprophylactic treatment.
Our goal was to assess the association between T-cell
responses and viremia in children after successful pro-
phylactic treatment.
HBV viremia stimulates host cellular immunity, and
CTLs can be involved in viral control [11,17]. The induc-
tion of HBV-core or polymerase-specific CTL indicates
that HBV infects host cells and that HBV proteins pre-
sented on the surface of the host cells are recognized as
targets by the host. In this study, 2 (15%) of 13 children
who were negative for HBsAg showed significant
responses in IFN-γ ELISPOT against HBV peptides.
Because HBV-specific peptides were derived for core and
polymerase protein in this study, these findings suggested
that HBV-specific T-cells were primed due not to hepati-
tis B vaccine but to the infection with HBV. In addition,
one of the 2 children in whom HBV-specific T-cell
responses were detectable was positive for serum HBV
DNA. Although the levels of serum HBV DNA were low,
viremia persisted despite HBV-specific T-cells and anti-
HBs remaining detectable. These findings were similar to
those in patients who suffered from acute HBV infection
Table 3: The frequency of children positive for IFN-γ enzyme-linked immunosorbent spot assay HLA-A24 hepatitis B virus-
specific cytotoxic T-cell epitope.
HLA-A24 hepatitis B virus-specific cytotoxic T-cell epitope
core 117-125
No. of children
(%)
pol 756-764
No. of children
(%)
Hepatitis B
surface antigen-positive
children
n = 3
0 (0) \ 0 (0) \
P = 0.41
P = 0.81
Hepatitis B
surface antigen-negative
children
n = 13
1 (7.7) / 2 (15.4) /
Table 4: Pentamer assay in the hepatitis B virus carrier mothers and hepatitis B surface antigen-negative children after 
successful prophylactic treatment of mother-to-child transmission.
Pentamer/CD8
mean ± SD (%)
core 117-125 pol 756-764
Mother (n = 5) 0.004 ± 0.005 0.001 ± 0.002
Children (n = 13) 0.003 ± 0.005 0.002 ± 0.002Komatsu et al. BMC Infectious Diseases 2010, 10:103
http://www.biomedcentral.com/1471-2334/10/103
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[20,21]. In acute HBV infection, clinical recovery does
not imply the complete clearance of serum or intrahe-
patic HBV DNA. The authors of previous studies
reported that HBV viremia persisted and anti-viral T-cell
responses were detectable for several years after resolu-
tion of acute hepatitis B [20-22]. The levels of serum HBV
DNA are usually low after acute hepatitis B.
In animal models of acute hepatitis B, functional T-cell
responses were generated after infection using high doses
of inoculated virus [23]. The results of one previous study
suggested that exposure to a low viral load allows persis-
tent viremia without priming functional T-cells [24]. Sim-
ilarly, detection of functional T-cells might be closely
related to the load of HBV to which children are exposed
before, during, and after prophylactic treatment. How-
ever, the mothers of the 2 children in whom HBV-specific
T-cells were detected were negative for HBeAg. Because
HBeAg-negative mothers usually have a low viral load
(Table 1), viral exposure alone might not explain the
induction of HBV-specific T-cells in children. Some stud-
ies suggested that HBeAg might induce T cell tolerance in
vertical transmission [25]. Therefore, viral genome muta-
tions such as precore mutants, which are unable to
secrete HBeAg, could be associated with the outcome of
mother-to-child transmission [26]. In C4, ELISPOT
showed a positive result for polymerase protein but not
core protein. This finding was consistent with that of a
previous study, in which some patients showed positive
results for both peptides and others showed positive
results for only one peptide in acute HBV infection [17].
Although CTL responses are restricted with the HLA
type, CTL responses to viral epitopes were different in
each individual.
Various studies have been performed using PCR to
evaluate the efficacy of immunization against HBV in
infants born to HBV carrier mothers [9,10]. In a previous
study, 2 of 29 (7%) children who received HBIG and hepa-
titis B vaccine and became negative for HBsAg and posi-
tive for anti-HBs were positive for serum HBV DNA [9].
Of the 2 children, one was free of HBV viremia 2 years
later. The other child became positive for HBsAg and
negative for anti-HBs later, because the mutation in the
"a" determinant of the S region occured. In another study,
serum HBV DNA was detected at 4-6 years after birth by
PCR in 14 of 94 (14%) children who received prophylactic
treatment [10]. Of the 14 children, 7 were negative for
HBsAg and positive for anti-HBs. Three of the 7 children
showed a high viral load (> 105  copies/mL), and the
remaining 4 children showed a low viral load (< 200 cop-
ies/mL). In the present study, real-time PCR was adopted
to detect serum HBV DNA, as real-time PCR can be
more sensitive than conventional PCR. In addition,
serum HBV DNA was quantified more accurately. Serum
HBV DNA was detected in 4 of 13 (31%) children in our
study, but the levels of HBV DNA were between 100 and
80 copies/mL. The prevalence rate of HBV viremia in this
study was higher than that in previous studies [9,10]. The
difference in the prevalence was presumably caused by
the difference in the detection limit of each PCR method.
Anti-HBc were detected in one of the 4 children with
viremia. However, the child was a 6-month-old boy. Prob-
ably, maternal anti-HBc were transferred to the child
through the placenta at birth [27]. Of the 4 children with
viremia, 3 were born to HBeAg-negative mothers. In gen-
eral, babies born to HBeAg-negative mothers are unlikely
to become HBV carriers, even if immunoprophylactic
treatment is not given. We cannot answer the question
why 3 of 4 children with viremia were born to HBeAg-
negative mothers. In a future study, the prevalence of
viremia in a large number of children who received suc-
cessful prophylactic treatment should be assessed.
A l t h o u g h  e s c a p e  m u t a n t s  h a v e  b e e n  a s s o c i a t e d  w i t h
persistence of serum HBV DNA after acute hepatitis B,
t h e  a p p e a r a n c e  o f  a n  e s c a p e  m u t a n t  i s  u n c o m m o n  i n
acute hepatitis B. In a previous study, variants in the S
region were detected in 2 of 14 children who received
prophylactic treatment [10]. However, the 2 children
were positive for HBsAg, negative for anti-HBs antibod-
ies, and infected with a high viral load (>108 copies/mL).
The previous study results suggested that the majority of
patients with viremia were infected with wild-type HBV
after prophylactic treatment. Although we did not
sequence the S region, the mechanism of persistent vire-
mia in children after the appearance of anti-HBs antibody
might be different from that in children infected with
escape variants. The level of serum anti-HBs antibodies
considered protective is >10 mIU/mL [28]. In the present
study, the level of serum anti-HBsAb was < 10 mIU/mL in
4 of the 13 children who were negative for HBsAg after
p r o p h y l a c t i c  t r e a t m e n t .  A l t h o u g h  i t  i s  c o n t r o v e r s i a l
whether booster vaccination is required to maintain ade-
quate levels of anti-HBs antibodies [28-30], all of the 4
children were negative for serum HBV DNA. All of these
children had levels of anti-HBs antibodies >10 mIU/mL
at 1 year after birth. However, the levels of anti-HBs anti-
bodies decreased to < 10 mIU/mL over time. None of the
4 children showed a significant HBV-specific T-cell
response. Further studies are needed to evaluate the role
of HBV-specific T-cell responses in children who lose
anti-HBs after prophylactic treatment.
The results of this study raise questions about the long-
term clinical impact of a low-dose HBV infection in chil-
dren. For instance, children with a low-dose infection
could suffer from hepatocelluar carcinoma in the future.
In addition, the new emerging biological therapies for
immunomodulation, including tumor necrosis factor
inhibitors and anti-B cell agents such as Rituximab, will
induce reactivation of HBV with a potentially fatal out-Komatsu et al. BMC Infectious Diseases 2010, 10:103
http://www.biomedcentral.com/1471-2334/10/103
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come in adult patients with chronic HBV infection or
occult HBV infection [31,32]. Because this study was
cross-sectional, we could not answer these questions.
Longitudinal studies in children receiving prophylactic
treatment are necessary to properly assess these issues
and answer these questions.
Conclusion
In conclusion, HBV core and polymerase-specific T-cell
responses were detectable in children after the appear-
ance of anti-HBs antibodies, although rarely. Moreover, a
low-level viremia was observed in nearly 1 in 3 children.
Although the presence of a low-level viremia was not
related to HBV-specific T-cell responses, our study
results showed that CTLs might play a role in the control
of HBV infection in children born to HBsAg-positive
mothers after immunoprophylactic treatment. Because
the number of subjects in the present study was small,
additional studies are required to evaluate virological and
immunological issues, including the role of CTLs in chil-
dren after immunoprophylactic treatment.
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